-
Mashup Score: 1No Improvement From Adjuvant Radiotherapy Post-Prostatectomy for Patients With Prostate Cancer At Risk of Recurrence - 4 day(s) ago
According to long-term results from the RADICALS-RT study, adjuvant radiotherapy does not meaningfully improve disease control and increases the risk of urinary and bowel morbidities among patients with prostate cancer at risk of recurrence after prostatectomy.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
According to results from the ongoing phase 1 TROPION-PanTumor01 trial, datopotamab deruxtecan demonstrated promising efficacy and safety among heavily pretreated patients with advanced or metastatic HR-positive, HER2-negative, or triple-negative breast cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Addition of Vismodegib to Radiation Therapy Shows Promise Among Patients With Basal Cell Carcinoma - 11 day(s) ago
Results from a prospective, phase 2 study found the addition of induction and concurrent vismodegib to radiation therapy may be considered a therapeutic option for patients with locally advanced, unresectable basal cell carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas - 18 day(s) ago
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence after surgical resection.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer - 20 day(s) ago
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced, unresectable vulvar squamous cell carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
According to Neil Horowitz, MD, and coauthors, "compared with historic results, the addition of gemcitabine to cisplatin once per week given concurrently with [intensity-modulated RT] significantly improved the [pCR]." Learn more: https://t.co/aSZNAGXIiY #medtwitter #onctwitter https://t.co/4A9aDPWVOZ
-
-
Mashup Score: 0Second- or Third-Line Giredestrant Among Patients With ER-Positive, HER2-Negative Advanced Breast Cancer - 28 day(s) ago
According to results from the phase 2 acelERA breast cancer study, giredestrant showed a favorable trend toward benefit in investigator-assessed progression-free survival among previously treated patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
As @MiguelEspMartin, MD, PhD, and coauthors concluded, "there was a consistent treatment effect with giredestrant across most key subgroups and a trend toward favorable benefit among patients with ESR1-mutated tumors." Learn more: https://t.co/XOj58MoZg6 #medtwitter #onctwitter https://t.co/Wbr9PvmZSV
-
-
Mashup Score: 0Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL - 28 day(s) ago
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo allogeneic stem cell transplantation.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Adjuvant Alectinib Significantly Improved Disease-Free Survival Among Patients With Resected ALK-Positive Non-Small Cell Lung Cancer - 29 day(s) ago
According to results from the phase 3 ALINA trial, adjuvant alectinib significantly improved disease-free survival among patients with resected ALK-positive stage IB, II, or IIIA non-small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
According to Chris Parker, MD, and coauthors, "An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy." Learn more: https://t.co/XTXd7nU21p #medtwitter #onctwitter https://t.co/4QupmQog6y